Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma

Drug Profile

Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma

Alternative Names: BI1029539; OX-MPI

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biolipox
  • Developer Biolipox; Boehringer Ingelheim
  • Class Anti-inflammatories
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Pain; Rheumatoid arthritis
  • Discontinued Fever; Osteoarthritis

Most Recent Events

  • 02 Oct 2017 Gesynta Pharma acquires the assets relating to the OX MPI programme from Orexo
  • 06 Aug 2014 Boehringer Ingelheim terminates its license for research programme: prostaglandin E synthase inhibitors
  • 16 Dec 2010 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top